Brief: Nuvation Bio Doses First Patient In Phase 1/2 Study Of NUV-1511
14/03/2024 21:31
March 14 (Reuters) - Nuvation Bio Inc NUVB.N :
* NUVATION BIO DOSES FIRST PATIENT IN PHASE 1/2 STUDY OF
NUV-1511
FOR THE TREATMENT OF ADVANCED SOLID TUMORS
Source text for Eikon: ID:nBw6kS0csa
Further company coverage: NUVB.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth